SCM
TEVA icon

Steadfast Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Steadfast Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-475,461
Closed -$14.8M – 113
2025
Q4 		$14.8M Sell
475,461
-322,539
-40% -$7.95M 0.25% 60
2025
Q3 		$16.1M Buy
+798,000
New +$14M 0.28% 57

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steadfast Capital Management's TEVA Position: Q1 2026 in Review

Steadfast Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 475,461 shares — an estimated $14.8M sold.

Steadfast Capital Management first reported a position in TEVA in Q3 2025 and held it in 2 quarters. The position peaked at $16.1M in Q3 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Steadfast Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Steadfast Capital Management sold 475,461 Teva Pharmaceuticals shares in Q1 2026, an estimated $14.8M.
  • Steadfast Capital Management first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Steadfast Capital Management's Teva Pharmaceuticals position peaked at $16.1M in Q3 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Steadfast Capital Management's 13F filing for Q1 2026, filed 15 May 2026.